Berns J
US$ 24.94
glp-1 ra medications New Guidelines for Type 2 Diabetes in 2025 GLP-1: Genetic Variants Related to
Description
Effect of obesogenic medications on weight-loss outcomes in a behavioral weight-management program
10.1002/cne.902710405 52 KanoskiS
Conclusion: The outlook for state Medicaid coverage of GLP-1 AOMs While 13 state Medicaid programs covered at least one GLP-1 approved for weight management as of August 2024, states subsequently reversed course: California, New Hampshire, Pennsylvania, and South Carolina recently withdrew coverage
Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with Type 2 diabetes and obesity
